Zavegepant is a next-generation CGRP receptor antagonist and certified reference standard used in the study and treatment of acute migraine. As the active pharmaceutical ingredient developed under the code names BHV-3500 and BMS-742413, Zavegepant has been investigated in phase 3 clinical trials for intranasal administration in migraine patients. In pharmaceutical quality control contexts, Zavegepant serves as the primary reference standard for impurity profiling and analytical method development. Zavegepant is recognized through multiple regulatory designations including INN, USAN, and WHO-DD, making it indispensable for regulatory submissions and quality control testing. The drug substance Zavegepant exhibits excellent stability when stored under recommended conditions at 4°C or –20°C in solution. Furthermore, Zavegepant joins the class of "-gepant" drugs as an additional treatment alternative for migraine patients, particularly those for whom traditional triptan therapy has proven ineffective.
|
Parameter |
Specification |
|
Product Name |
Zavegepant |
|
CAS Number |
1337918-83-8 |
|
Molecular Formula |
C₃₆H₄₆N₈O₃ |
|
Molecular Weight |
638.80 g/mol |
|
Appearance |
White to off-white solid |
|
Boiling Point |
933.7±65.0 ℃ |
|
|
Zavegepant works by specifically inhibiting the binding of CGRP to its receptor within the trigeminal neurovascular system, thereby blocking this critical neuropeptide-mediated vasodilation and pain signal transduction, which rapidly alleviates migraine attacks. As the world's first CGRP receptor antagonist available as a nasal spray, Zavegepant provides a novel rapid-acting treatment option for over 1 billion migraine patients without requiring injections or oral administration—making it particularly suitable for patients who experience nausea or vomiting and find oral medication difficult to tolerate. Pfizer is currently advancing the clinical development of its oral formulation, aiming to further expand the range of available delivery methods.
Q1: What is the mechanism of action of Zavegepant?
A: Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It binds to the CGRP receptor with high affinity, blocking the activity of CGRP—a neuropeptide that plays a key role in migraine pathophysiology.
Q2: What are the primary therapeutic indications for Zavegepant?
A: Zavegepant is being developed for the acute treatment of migraine. It has also been investigated for its potential to combat acute respiratory distress syndrome (ARDS) in hospitalized COVID-19 patients due to CGRP's role in acute lung injury.
Partner with Cosperpharm for Zavegepant that meets the highest standards of purity, documentation, and supply reliability. Whether you are advancing migraine research, developing analytical methods, or scaling up production, our team is ready to support your success.
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
